Bitterman Kevin

Director Kevin Bitterman sold 184,123 shares (92.9% of holdings) in 19 transactions for $16,858,639.38, reducing stake from 198.3K to 14.2K shares.

Kevin Bitterman, Director at Disc Medicine (IRON), executed 19 separate sales across December 12–16, 2025, totaling 184,123 shares for $16,858,639.38 at a blended average price of $91.56. This represents a near-complete liquidation, reducing his holdings from 198.3K shares to 14.2K shares (a 92.9% reduction). The timing coincides with the stock near its 52-week high of $94.11 (current price $91.47 is only 2.8% below peak), and the company remains unprofitable with full-year net income of $-62,321,000.00. While his cross-ticker track record shows an average 30-day return of +6.5% following prior sells, his five measurable sales at IRON on 2025-10-17 have shown mixed outcomes (ranging from -2.1% to +4.4% over 30 days), with no 90-day track record yet established at this ticker to assess selling timing patterns. The scale and structure of this liquidation—nearly complete, executed at near-peak prices, in an unprofitable company—merits investor scrutiny of the underlying business catalyst and director sentiment.

Director Bitterman sold 93,585 shares (93.6K) at blended avg $85.97 for $8.0M in 17 transactions over 3 days ending 2025-10-17

Kevin Bitterman, a Director at Disc Medicine, executed 17 separate sales totaling 93,585 shares for $8,045,251.74 over October 15–17, 2025, reducing his holdings by 19.5% to 385,549 shares. The sales occurred at prices ranging from $77.11 to $91.88, with a blended average of $85.97, near the current price of $89.94 at the high end of the 52-week range ($34.28–$89.94). Notably, his prior 5 trades at IRON (October 8) were also sales with outcomes not yet measurable, establishing a pattern of sequential liquidation. His cross-ticker track record shows 19 prior sells with a 50.00% well-timed rate and a negative 90-day average return of -23.5%, indicating historically mixed timing effectiveness, yet the company itself reported a net loss of $-55,247,000.00 for the most recent full fiscal year, adding fundamental context to director-level equity disposition activity.

Director Bitterman sells 90,000 shares ($6.3M) at $70.14 average; stock near 52-week high, insider's recent IRON sales averaging -1.6% 30d returns

Kevin Bitterman executed 7 separate sales totaling 90,000 shares for $6,312,500.51 across October 7–8, 2025, reducing his post-transaction holdings to 500.6K shares (-15.2% vs pre-transaction). The sales occurred as IRON traded at $70.75, matching its 52-week high, and at blended average price of $70.14 near that peak. His same-ticker history at IRON shows 4 prior recent sells (July 23, July 24, August 13, August 14) averaging -1.6% 30-day returns, establishing a pattern of selling into strength without subsequent upside capture. The company reported net income of -$55,247,000 over its most recent full fiscal year, indicating material operational losses amid a $2.5B market cap. Context: stock has rallied +17.2% over 30 days and +24.3% over 90 days, yet the director continues a multi-week cadence of equity liquidation near peak valuation levels.

Director Kevin Bitterman sold 32,174 shares ($2.0M) at $61.11 avg; stock now $59.86 amid unprofitable fundamentals.

Kevin Bitterman, Director of IRON, executed 2 separate sales totaling 32,174 shares (32.2K shares) for $1,966,286.18 ($2.0M) on 2025-08-13 and 2025-08-14, at a blended average price of $61.11. He retains 592,908 shares (592.9K shares) post-transaction, representing a 5.1% reduction in holdings. The stock has since declined to $59.86 (current price), now trading -11.3% from the 52-week high. Notably, the company reported negative net income of $-55,247,000.00 ($-55.2M) over its most recent full fiscal year, underscoring unprofitable fundamentals. Across his same-ticker history at IRON, Bitterman demonstrated strong prior timing execution (3 of 3 prior measurable trades well-timed at the 90-day horizon), including a June 2024 buy that returned +32.8% over 90 days and two prior 2024 sells that preceded declines, though his cross-ticker selling average shows a well-timed rate of only 43.75%—below 50% threshold.

Director Kevin Bitterman sold 42,870 shares ($2.6M) in 2 transactions at $60.97–$61.17 on July 23–24, 2025

Director Kevin Bitterman executed two separate sales totaling 42,870 shares for $2,616,390.50, reducing his holdings by 6.3% to 633,969 shares. The sales occurred at $60.97 on 2025-07-23 and $61.17 on 2025-07-24, averaging $61.03, while the current price stands at $60.61 (marginally below transaction prices). Within a 90-day window, Bitterman's prior trades at IRON demonstrate strong execution: 5 of 5 prior trades were well-timed at the 90-day mark, including a June 2024 buy that appreciated 32.8% and three prior sells that captured downturns averaging -50% to -60% in the 90-day period. The company remains unprofitable with net income of $-34,085,000.00, and the stock has recovered 33.4% over 90 days from a depressed level. Bitterman's demonstrated pattern of selling before significant declines, combined with the unprofitable fundamentals and the near-peak valuation (10.2% below the 52-week high of $67.47), suggests this director continues his pattern of reducing exposure ahead of potential weakness.

Director Kevin Bitterman buys 222,223 shares of IRON at $36.00 for $8,000,028.00; post-buy holdings 420,549 shares (+112.0%)

Kevin Bitterman, Director, purchased 222,223 shares at $36.00 on 2024-06-17, more than doubling his holdings from 198,326 to 420,549 shares. The stock has since risen to $41.25 (+32.0% in 30 days) after trading as high as $75.32 in the past 52 weeks, though it remains -45.2% below that peak. Critically, the company posted a full-year net loss of $-26,949,000.00 on a market cap of $1,019,768,722.50. The purchase coincides with a cluster pattern: 2 other insiders also bought within the past 14 days. His prior trading record at IRON shows 4 of 5 prior sells were well-timed at the 90-day mark (stock declined after), yet his cross-ticker sell track record averages a -11.0% 90-day return with a 43.75% well-timed rate.